- ABOUT ME
- AREAS OF FOCUS
- EDUCATION & LEADERSHIP
- LOCATIONS & HOSPITALS
- NEWS & PUBLICATIONS
Dr. Michael Chew has a special interest in working with patients on nutrition and is board certified in obesity medicine. He has extensive training in advanced liver disease with an emphasis on treating portal hypertension complications including varices, variceal hemorrhage, ascites, and spontaneous bacterial peritonitis (SBP). Dr. Chew has conducted research with a leading expert in liver disease, evaluating non-invasive methods for diagnosing cirrhosis.
Dr. Chew appreciates Portland’s sense of community and family friendly vibe. He enjoys the walkability of the neighborhoods, and easy access to parks and trails. Outside of work, Dr. Chew spends time with his wife and two boys, going to farmer’s markets, hiking, traveling, and playing tennis.
Other Activities
American Gastroenterological Association (AGA)
American Association for the Study of Liver Diseases (AASLD)
American College of Physicians (ACP)
American Society for Gastrointestinal Endoscopy (ASGE)
American Board of Obesity Medicine (ABOM)
Areas of Focus
Colon Cancer Screening & Prevention
Inflammatory Bowel Disease (IBD)
Irritable Bowel Syndrome (IBS)
Gastroesophageal Reflux Disease (GERD)
Eosinophilic Esophagitis (EoE)
Microscopic Colitis
Liver Disease
Human Nutrition
Obesity Medicine
EDUCATION & TRAINING
Gastroenterology and Hepatology Fellowship, Yale University, 2022
Internal Medicine Residency, University of California, Davis, 2017
MD, University of California, Davis, 2014
MS, Columbia University, 2010
BS, University of California, Berkeley, 2008
BOARD CERTIFICATION
Gastroenterology
Internal Medicine
Obesity Medicine
HONORS
UC Davis Internal Medicine Residency Professionalism Award
California Alumni Leadership Award
Edith G. Stokstad Memorial Award in Nutritional Sciences
Locations
Hospitals Served
- Providence St. Vincent Medical Center
Publications
Chew M, Garcia-Tsao G. Reply. Clin Gastroenterol Hepatol. 2021 Jun 18: S1542-3565(21)00603-0. doi:10.1016/j.cgh.2021.05.064.
Vianna, A, Chew, M. Commentary on “Semaglutide increase NASH Resolution but Does Not Improve Fibrosis Stage.” Practice Update Diabetes. Vol. 5. No 1. 2021.
Chew M, Tang Z, Radcliffe C, Caruana D, Doilicho N, Ciarleglio MM, Deng Y, Garcia-Tsao G. Significant Liver Injury During Hospitalization for COVID-19 Is Not Associated with Liver Insufficiency or Death. Clin Gastroenterol Hepatol. 2021 May 15:S1542-3565(21)00525-5. doi: 10.1016/j.cgh.2021.05.022.
Bajaj JS, Garcia-Tsao G, Wong F, Biggins SW, Kamath PS, McGeorge S, Chew M, Pearson M, Shaw J, Kalluri A, Fagan A, Olofson A, Moini M, de la Rosa Rodriguez R, Reddy KR. Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID-19: A Multicenter Cohort. Liver Transpl. 2021 Jan 11:10.1002/lt.25981. doi: 10.1002/lt.25981.
Bajaj JS, Garcia-Tsao G, Biggins SW, Kamath, PS, Wong, F, McGeorge S, Shaw J, Pearson M, Chew M, Fagan A, Rodriguez R, Worthington J, Olofson A, Weir V, Trisolini C, Dwyer S, Reddy R. Comparison of mortality risk in patients with cirrhosis and COVID- 19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut 2021;70:531-536